知镜 Cognispect · 医学文献与研究工作台

Aldo-keto reductase family 1 member B10 in solid tumors: lipid metabolic reprogramming, immune remodeling, and targeted therapy.

Chen Y, Mi L, Shi J, Zhao M, Yin F.
Biochemical pharmacology · 2026-11-13 · PMID 43025710

文献摘要

Aldo-keto reductase family 1 member B10 (AKR1B10), an NADPH-dependent aldo-keto reductase, has emerged as a context-dependent metabolic stress regulator with important implications for therapeutic resistance and tumor immune remodeling in solid tumors. By neutralizing lipid-derived aldehydes such as 4-hydroxynonenal (4-HNE), AKR1B10 limits lipid-derived carbonyl stress and may reduce ferroptosis susceptibility in defined tumor contexts. It also stabilizes acetyl-CoA carboxylase α, thereby sustaining de novo lipogenesis (DNL). In addition, AKR1B10 has been linked to increased glycolysis-associated lactate production in specific tumor settings. This increase in lactate can promote histone lactylation-mediated epigenetic reprogramming. Together with reported associations between AKR1B10 and immune-cell infiltration or function, these metabolic effects may contribute to tumor immune remodeling in a context-dependent manner. Aberrant AKR1B10 expression has been associated with tumor progression and therapeutic resistance in several solid tumors, including hepatocellular carcinoma, non-small-cell lung cancer, pancreatic ductal adenocarcinoma, and cholangiocarcinoma. This review systematically examines the structural biology, transcriptional regulation, and tumor-intrinsic and microenvironmental functions of AKR1B10. It further evaluates its tumor-type-specific diagnostic and prognostic potential and discusses emerging inhibitor strategies. Nonetheless, key challenges remain, including the tissue-specific functional duality of AKR1B10, the demand for inhibitors selective over the structurally homologous AKR1B1, and limited causal evidence linking AKR1B10 to immune remodeling in tumors. Future research should integrate multimodal spatial omics, immunocompetent tumor models, and rational combination therapy designs to advance AKR1B10 from a metabolic enzyme into a clinically actionable target for precision oncology.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。